Cancer Clinical Trials: Proactive Strategies

  • Stanley P. L. Leong
Part of the Cancer Treatment and Research book series (CTAR, volume 132)

Table of contents

  1. Front Matter
    Pages i-xix
  2. Scott Kurtzman, Zita Lazzarini
    Pages 11-30
  3. Jeffrey S. Abrams, Anthony Murgo, Michaele C. Christian
    Pages 31-50
  4. Steven Hirschfeld
    Pages 51-109
  5. Ann M. Mauer, Elizabeth S. Rich, Richard L. Schilsky
    Pages 111-129
  6. Y. Nancy You, Lisa Jacobs, Elizabeth Martinez, David M. Ota
    Pages 179-197
  7. John M. Harrelson, John M. Falletta
    Pages 199-207
  8. Gerianne J. Sands, Peggy A. Means
    Pages 219-229
  9. Peter Abbrecht, Nancy Davidian, Samuel Merrill, Alan R. Price
    Pages 231-239
  10. Larry Carbone, Scott H. Kurtzman, Stanley P. L. Leong
    Pages 291-309
  11. Back Matter
    Pages 311-319

About this book

Introduction

Foreword written by Samuel A. Wells, Jr., MD
Professor of Surgery
Duke University Medical Center, Durham, NC

According to the American Cancer Society, about 1 million persons in the United States will be diagnosed with solid cancer every year. About 50% of them will be potentially cured by surgery. The other half of the population may develop metastatic cancer. To date, there is no systemic treatment available to cure metastatic cancer. Therefore, cancer clinical trials are critical to evaluate reliable treatment modalities against metastatic cancer. Likewise, adjuvant trials are needed to prevent high risk patients from developing recurrence following definitive surgical resection of their cancer. Only about 3-5% of the adult cancer patients are enrolled in clinical trials. When the pediatric cancer clinical trial groups were able to accrue over 40 percent of eligible patients to their clinical trials, significant impact was made on the survival of these pediatric cancer patients. However, multiple barriers exist to block adult cancer patients from entering into clinical protocols. The ever-changing regulations for clinical trials and the ethical dilemma of treating cancer patients as subjects have made it ever so difficult for the principal investigators to conduct clinical research, especially when they are often ill-informed of the complex nature of the regulations and over-worked. Therefore, cancer clinical trials are at a critical junction. The objective of this book is to bring the issues of cancer clinical trials into focus so that proactive strategies may be developed to make such trials more user-friendly. Ultimately, the cancer patients will be benefited.

"Clinical trials remain the most important vehicle for improving the care of cancer patients. This text presents the fundamental components and challenges involving clinical investigations. Leading experts discuss the critical issues covering the spectrum of important topics from planning to application."

Steven T. Rosen, M.D.
Series Editor

Keywords

breast cancer cancer cancer research cancer therapy clinical trial oncology surgery

Editors and affiliations

  • Stanley P. L. Leong
    • 1
  1. 1.Department of SurgeryUniversity of California Medical Center at Mount ZionSan Francisco

Bibliographic information

  • DOI https://doi.org/10.1007/978-0-387-33225-3
  • Copyright Information Springer Science+Business Media, LLC 2007
  • Publisher Name Springer, Boston, MA
  • eBook Packages Medicine
  • Print ISBN 978-0-387-33224-6
  • Online ISBN 978-0-387-33225-3
  • Series Print ISSN 0927-3042
  • About this book